Non-anti TNF biologic modifier drugs in non-infectious refractory chronic uveitis: the current evidence from a systematic review

Gelijkaardige items

• Current evidence of MTX efficacy in childhood chronic uveitis: a systematic review and meta-analysis
  door: Simonini, G, et al.
  Gepubliceerd in: (2011)
• Superior efficacy of Adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: Adalimumab as starting anti-TNF-α therapy in childhood chronic uveitis
  door: Simonini, Gabriele, et al.
  Gepubliceerd in: (2013)
• PReS-FINAL-2347: Does switching anti-TNFΑ biologic agents an effective option in childhood chronic uveitis: the evidence from a systematic review and meta-analysis approach
  door: Simonini, G, et al.
  Gepubliceerd in: (2013)
• PReS-FINAL-2327: Abatacept in the treatment of refractory uveitis
  door: Moretti, D, et al.
  Gepubliceerd in: (2013)
• PReS-FINAL-2211: NOD2/CARD15 polymorphisms and clinical features in patients with non-infectious uveitis
  door: Marrani, E, et al.
  Gepubliceerd in: (2013)